Jiangsu Cowin Biotech News

Kang Weishi (688426): 2023 Report & 2024 Quarterly Report Reviews Short-term Pressure Optimizes the Potential of Helicobacter Pylori Drug Resistance Test Series

東吳證券May 8 07:26

Kangwei Century (688426): Molecular testing industry chain layout Helicobacter pylori stool test creates a second growth curve

東吳證券Feb 28 15:21

Kang Wei Century (688426): Xiaolongtou, a raw material for molecular testing, digestive tract testing is the next blue ocean of development

方正證券Aug 30, 2023 07:42

Kangwei Century (688426) Company's first coverage report: Helicobacter pylori testing products based on the upstream molecular testing market are expected to open the company's rapid growth curve

開源證券Apr 20, 2023 00:00

Kangwei Century (688426) Company Dynamic Research Report: Mastering the Underlying Innovative Core Technology of Nucleic Acid Testing and Laying Out the Helicobacter Pylori Testing Market

華鑫證券Mar 6, 2023 00:00

Kangwei Century (688426) IPO Coverage Research

華金證券Sep 29, 2022 00:00